Envestnet Asset Management
TARS icon

Envestnet Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Envestnet Asset Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$799K Buy
12,696
+1,092
+9% +$69.8K ﹤0.01% 3758
2026
Q1 		$814K Buy
11,604
+2,314
+25% +$162K ﹤0.01% 3598
2025
Q4 		$761K Buy
9,290
+205
+2% +$15.3K ﹤0.01% 3430
2025
Q3 		$540K Sell
9,085
-1,271
-12% -$62.6K ﹤0.01% 3709
2025
Q2 		$420K Buy
10,356
+1,418
+16% +$63.8K ﹤0.01% 3832
2025
Q1 		$459K Sell
8,938
-3,195
-26% -$158K ﹤0.01% 3682
2024
Q4 		$672K Sell
12,133
-2,282
-16% -$104K ﹤0.01% 3412
2024
Q3 		$474K Buy
14,415
+3,878
+37% +$109K ﹤0.01% 3563
2024
Q2 		$286K Sell
10,537
-692
-6% -$23.3K ﹤0.01% 3759
2024
Q1 		$408K Buy
+11,229
New +$330K ﹤0.01% 3558

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Envestnet Asset Management's TARS Position: Q2 2026 in Review

Envestnet Asset Management increased its Tarsus Pharmaceuticals (TARS) stake by 9.4% in Q2 2026, buying an estimated $69.8K and bringing the position to 12,696 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #3758.

Envestnet Asset Management first reported a position in TARS in Q1 2024 and has held it in 10 quarters since. The position peaked at $814K in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Envestnet Asset Management held 12,696 shares of Tarsus Pharmaceuticals worth $799K as of Q2 2026.
  • Envestnet Asset Management bought 1,092 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $69.8K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #3758 holding.
  • Envestnet Asset Management first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Envestnet Asset Management's Tarsus Pharmaceuticals position peaked at $814K in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.